What should be monitored during a treatment visit for a patient receiving durvalumab (Imfinzi)?

Monitoring During Durvalumab Treatment Visits

Monitor patients receiving durvalumab at each treatment visit for signs and symptoms of immune-related adverse events (irAEs), with particular attention to pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, and dermatologic reactions, along with baseline and serial laboratory assessments. 1

Clinical Symptom Surveillance

At every visit, systematically question patients about new or worsening symptoms across multiple organ systems:

Pulmonary Monitoring (Pneumonitis - Most Critical)

• New or worsening cough, chest pain, or shortness of breath 1
• Pneumonitis is a leading cause of durvalumab discontinuation (53.7% in one series) 2
• Grade ≥3 pneumonitis occurs in approximately 2.4-3.1% of patients 2, 3

Gastrointestinal Monitoring

• Diarrhea: Quantify increase in stool frequency over baseline 1
• Blood or mucus in stools 1
• Severe abdominal pain, cramping, nausea 4, 1
• Fever, abdominal distention, or constipation 4

Hepatic Monitoring

• Jaundice (yellowing of skin or eyes) 1
• Severe nausea or vomiting 1
• Right upper quadrant abdominal pain 1
• Easy bruising or bleeding 1

Endocrine Monitoring

Screen for multiple potential endocrinopathies 4, 1:

• Thyroid dysfunction: Heat/cold intolerance, palpitations, weight changes, hair loss, voice deepening
• Adrenal insufficiency: Extreme fatigue, dizziness, fainting, loss of appetite
• Diabetes: Polyuria, polydipsia, extreme fatigue
• Hypophysitis: Persistent headaches, visual changes, unusual fatigue

Renal Monitoring

• Decreased urine output 1
• Blood in urine 1
• Ankle swelling 1

Dermatologic Monitoring

• New rash or itching 1
• Skin blistering or peeling 1
• Painful oral, nasal, throat, or genital ulcers 1

Musculoskeletal and Neurologic Monitoring

• Muscle pain, weakness, or cramps 4, 1
• Joint pain, swelling, or stiffness 4
• Tingling, numbness, or weakness in extremities 1
• Vision changes, double vision, or eye pain 1

Cardiac Monitoring

• Chest pain, irregular heartbeat, or new shortness of breath 1
• Myocarditis, though rare, carries high mortality when combined with myositis/myasthenia gravis 4

Laboratory Monitoring

Baseline and Serial Testing

At each treatment cycle, obtain: 4

• Complete blood count (CBC) with differential
• Comprehensive metabolic panel (CMP) including liver function tests (AST, ALT, bilirubin, alkaline phosphatase) and renal function (creatinine, BUN)
• Thyroid function tests (TSH) at baseline and with each cycle 4
• Glucose monitoring at baseline and each cycle (continue for at least 6 months after completion) 4

Additional Testing When Indicated

• Morning cortisol and ACTH if adrenal insufficiency suspected 4
• Inflammatory markers (ESR, CRP) if arthritis symptoms present 4
• Fecal calprotectin or lactoferrin for persistent diarrhea/colitis 4
• Creatine kinase (CK) if myositis suspected 4

Infusion Reaction Monitoring

During and immediately after infusion (especially first 4 cycles), monitor for 5, 1:

• Chills, shaking, fever
• Flushing, itching, rash
• Shortness of breath, wheezing
• Dizziness, feeling faint
• Back or neck pain

Durvalumab has lower infusion reaction rates (2.2%) compared to other checkpoint inhibitors, but vigilance remains essential 5.

Critical Pitfalls to Avoid

1. Do not dismiss mild symptoms: Grade 1 toxicities can rapidly progress. Early recognition prevents severe complications 4

2. Timing matters: irAEs can occur at any point during treatment or even months after completion 5. Maintain vigilance throughout and beyond the treatment period.

3. Multiple simultaneous irAEs: Patients can develop more than one immune-related toxicity concurrently 1

4. Steroid masking: Patients on corticosteroids for one irAE may develop adrenal insufficiency; test HPA axis recovery after 3 months of maintenance therapy 4

5. Laboratory confirmation delays: In suspected adrenal crisis or severe irAEs, initiate treatment immediately—do not wait for confirmatory testing 4

Documentation Requirements

At each visit, document:

• Systematic review of symptoms by organ system
• Current laboratory values with trends
• Any new medications (especially NSAIDs, which increase colitis risk) 4
• Patient education reinforcement about when to seek immediate care
• Verification that patient has emergency contact information and understands stress-dosing if on corticosteroids 4